Abstract
Radiation nephropathy has emerged as a major complication of bone marrow transplantation (BMT) when total body irradiation (TBI) is used as part of the regimen. Classically, radiation nephropathy has been assumed to be inevitable, progressive, and untreatable. However, in the early 1990s, it was demonstrated that experimental radiation nephropathy could be treated with a thiol-containing ACE inhibitor, captopril. Further studies showed that enalapril (a non-thiol ACE inhibitor) was also effective in the treatment of experimental radiation nephropathy, as was an AII receptor antagonist. Studies also showed that ACE inhibitors and AII receptor antagonists were effective in the prophylaxis of radiation nephropathy. Interestingly, other types of antihypertensive drugs were ineffective in prophylaxis, but brief use of a high-salt diet in the immediate post-irradiation period decreased renal injury. A placebo-controlled trial of captopril to prevent BMT nephropathy in adults is now underway. Since excess activity of the renin-angiotensin system (RAS) causes hypertension, and hypertension is a major feature of radiation nephropathy, an explanation for the efficacy of RAS antagonism in the prophylaxis of radiation nephropathy would be that radiation leads to RAS activation. However, current studies favor an alternative explanation, namely that the normal activity of the RAS is deleterious in the presence of radiation injury. On-going studies suggest that efficacy of RAS antagonists may involve interactions with a radiation-induced decrease in renal nitric oxide activity or with radiation-induced tubular cell proliferation. We hypothesize that while prevention (prophylaxis) of radiation nephropathy with ACE inhibitors, AII receptor antagonists, or a high-salt diet work by suppression of the RAS, the efficacy of ACE inhibitors and AII receptor antagonists in treatment of established radiation nephropathy depends on blood pressure control.
Keywords: angiotensin II receptors, ace inhibitors, captopril, kidney, radiation injuries, bone marrow transplant
Current Pharmaceutical Design
Title: ACE Inhibitors and AII Receptor Antagonists in the Treatment and Prevention of Bone Marrow Transplant Nephropathy
Volume: 9 Issue: 9
Author(s): J. E. Moulder, B. L. Fish and E. P. Cohen
Affiliation:
Keywords: angiotensin II receptors, ace inhibitors, captopril, kidney, radiation injuries, bone marrow transplant
Abstract: Radiation nephropathy has emerged as a major complication of bone marrow transplantation (BMT) when total body irradiation (TBI) is used as part of the regimen. Classically, radiation nephropathy has been assumed to be inevitable, progressive, and untreatable. However, in the early 1990s, it was demonstrated that experimental radiation nephropathy could be treated with a thiol-containing ACE inhibitor, captopril. Further studies showed that enalapril (a non-thiol ACE inhibitor) was also effective in the treatment of experimental radiation nephropathy, as was an AII receptor antagonist. Studies also showed that ACE inhibitors and AII receptor antagonists were effective in the prophylaxis of radiation nephropathy. Interestingly, other types of antihypertensive drugs were ineffective in prophylaxis, but brief use of a high-salt diet in the immediate post-irradiation period decreased renal injury. A placebo-controlled trial of captopril to prevent BMT nephropathy in adults is now underway. Since excess activity of the renin-angiotensin system (RAS) causes hypertension, and hypertension is a major feature of radiation nephropathy, an explanation for the efficacy of RAS antagonism in the prophylaxis of radiation nephropathy would be that radiation leads to RAS activation. However, current studies favor an alternative explanation, namely that the normal activity of the RAS is deleterious in the presence of radiation injury. On-going studies suggest that efficacy of RAS antagonists may involve interactions with a radiation-induced decrease in renal nitric oxide activity or with radiation-induced tubular cell proliferation. We hypothesize that while prevention (prophylaxis) of radiation nephropathy with ACE inhibitors, AII receptor antagonists, or a high-salt diet work by suppression of the RAS, the efficacy of ACE inhibitors and AII receptor antagonists in treatment of established radiation nephropathy depends on blood pressure control.
Export Options
About this article
Cite this article as:
Moulder E. J., Fish L. B. and Cohen P. E., ACE Inhibitors and AII Receptor Antagonists in the Treatment and Prevention of Bone Marrow Transplant Nephropathy, Current Pharmaceutical Design 2003; 9 (9) . https://dx.doi.org/10.2174/1381612033455422
DOI https://dx.doi.org/10.2174/1381612033455422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Preconception Care for the Type 2 Diabetic Mother: A Review on Current Care Guidelines
Current Women`s Health Reviews Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) To Enhance or to Inhibit Integrin Function in Angiogenesis, that is the Question
Current Angiogenesis (Discontinued) Prediction of Recurrence of Atrial Fibrillation Post-ablation Based on Atrial Fibrosis Seen on Late Gadolinium Enhancement MRI: A Metaanalysis
Current Cardiology Reviews Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy
Current Diabetes Reviews Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Editorial: (Thematic Issue: Vascular Pathophysiology of Alzheimer`s Disease)
Current Alzheimer Research Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus
Current Drug Therapy Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Lymphocytic Interstitial Pneumonia Associated with Sjögren Syndrome: Case-Based Review
Current Rheumatology Reviews Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Massively Parallel Screening of the Receptorome
Combinatorial Chemistry & High Throughput Screening